HC Wainwright Rates Zevra Therapeutics (ZVRA) buy

Analyst Brandon Folkes reaffirms a buy rating with a $26 target for Zevra Therapeutics, a 99.39% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 1:02 PM EDT · Updated Jun 26, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $26 price target on June 23, 2026.

Since the rating, $ZVRA is up 10.3% after 1 week, down 3.7% after 1 month and down 23.5% to date (from the $13 close on Jun 23, 2026).

ZVRA Zevra Therapeutics, Inc.

$9.94 +19.18% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright's Brandon Folkes reiterated a buy rating for Zevra Therapeutics with a $26 price target on June 23, 2026.
HC Wainwright's $26 price target implies 99.39% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $13.04 share price.
Zevra Therapeutics trades on NasdaqGS at around $12.86, with a market cap of approximately $748 million and a P/E ratio of 6.29.
Other analysts like Maxim Group and BTIG also maintain buy ratings, targeting prices as high as $35.

Get $ZVRA trade alerts by text

We text you when insiders, Congress or big funds trade $ZVRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating for Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) with a price target of $26. Analyst Brandon Folkes made this reaffirmation on June 23, 2026. With shares trading near $12.86 on Tuesday, this target suggests significant potential upside.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +52.69% hypothetical

All-time return +154.20% S&P 500 +27.44%

vs. S&P 500 +126.76% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Zevra Therapeutics, Inc. Stock Up 27.0%

Shares of NasdaqGS:ZVRA traded around $12.86 on Tuesday. Zevra Therapeutics boasts a market cap of approximately $748 million and has a P/E ratio of 6.29. The stock's beta is 0.894, indicating lower volatility compared to the market. Over the last 52 weeks, the stock has ranged from $7.16 to $14.27. Its 50-day moving average is $10.95, while the 200-day moving average is $9.59. Zevra's financial health is strong, with a current ratio of 4.89 and a quick ratio of 4.74, alongside a debt-to-equity ratio of 0.557.

12-month forecast

$ZVRA price target

Zevra Therapeutics, Inc. daily closes and this analyst's $26 target. Not advice.

Recent Earnings

Zevra Therapeutics reported revenue of $122.3 million, reflecting a growth rate of 77.5%. The company has a net margin of 101.58% and a return on equity of 100.65%. Earnings per share stand at $2.01. The next earnings release is expected on August 11, 2026.

Insider Buying and Selling at Zevra Therapeutics, Inc.

Several insiders at Zevra Therapeutics, including Tamara Favorito, Douglas Calder, Corey Michael Watton, Thomas Anderson, Alvin Shih, and Alicia Secor, each bought 30,000 shares on June 4, 2026. These transactions were not part of any planned trading program.

Analysts Set New Price Targets

On June 23, 2026, HC Wainwright & Co. reiterated its buy rating for Zevra Therapeutics, setting a $26 price target. Other firms like Canaccord Genuity and Maxim Group also maintained buy ratings, with targets of $29 and $35, respectively. The consensus among analysts is a strong buy, with a mean target price of $27.89 based on 9 analyst opinions.

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focusing on rare diseases. The company uses its Ligand Activated Technology platform to develop treatments. Its lead products include KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers Danlos syndrome. Zevra also offers AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. Led by CEO Neil F. McFarlane, Zevra was formerly known as KemPharm, Inc.

Bottom Line

HC Wainwright's reaffirmation of a buy rating for Zevra Therapeutics underscores confidence in the company's potential. With shares trading at $12.86, the $26 price target implies a notable upside. As a commercial-stage biotech firm, Zevra's focus on rare diseases and strong financials make it a company to watch. Remember, analyst ratings are based on past performance and expectations, and may not reflect future market conditions.